Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.58 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.58 |
| ▸ | THRB known ✓ | P10828 | 2/20 | 0.53 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.51 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.44 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.44 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.42 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.61 |
| ▸ | PHLPP2 | Q6ZVD8 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | BLVRB | P30043 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135508 | 1.00 | PLCG1 (0.61) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 | |
| SCHEMBL27727543 | 0.88 | PHLPP2 (0.60) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 | |
| Olsalazine SCHEMBL29767 | 0.87 | MEN1 (0.66) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 | |
| Olsalazine SCHEMBL3476110 | 0.87 | MEN1 (0.66) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 | |
| Olsalazine SCHEMBL29454399 | 0.87 | MEN1 (0.66) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 | |
| SCHEMBL17866569 | 0.84 | ALDH1A1 (0.48) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 | |
| Chrysamine G SCHEMBL15818024 | 0.84 | TDP1 (0.70) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 | |
| SCHEMBL29950230 | 0.83 | MEN1 (0.61) | PHLPP2PTGS2ALDH1A1PTGS1CYP2C9 | |
| SCHEMBL27985065 | 0.83 | MEN1 (0.61) | PHLPP2PTGS2ALDH1A1PTGS1CYP2C9 | |
| SCHEMBL10784910 | 0.82 | MEN1 (0.59) | PLCG1PHLPP2PTGS2ALDH1A1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743523-B1 | Dye-based reference material, preparation and use thereof | BAYER AG (US) | 2002-08-28 | — | — | EP | claimed |
| US-5891730-A | HEMOGLOBIN DIAGNOSIS | CHIRON DIAGNOSTICS CORPORATION (US) | 1999-04-06 | — | — | US | claimed |
| US-5637505-A | CALIBRATING OR QUALIFYING INSTRUMENT FOR DIAGNOSIS SPECTROSCOPIC | CHIRON DIAGNOSTICS CORPORATION (US) | 1997-06-10 | — | — | US | claimed |
| EP-0743523-A2 | Dye-based reference material, preparation and use thereof | Ciba Corning Diagnostics Corp. (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0618949-A1 | IONIC DYE-BASED ELECTRORHEOLOGICAL MATERIALS | LORD CORPORATION (US) | 1994-10-12 | — | — | EP | claimed |
| EP-0618949-A4 | IONIC DYE-BASED ELECTRORHEOLOGICAL MATERIALS. | LORD CORP (US) | 1994-07-07 | — | — | EP | claimed |
| US-5306438-A | Dielectric hydrophobic liquid carrier fluid with anionic dye particles; quick response | LORD CORPORATION (US) | 1994-04-26 | — | — | US | claimed |
| WO-1993019143-A1 | COLORANT-CONTAINING ELECTRORHEOLOGICAL MATERIALS | LORD CORPORATION (US) | 1993-09-30 | — | — | WO | claimed |
| WO-1993012192-A1 | IONIC DYE-BASED ELECTRORHEOLOGICAL MATERIALS | LORD CORPORATION (US) | 1993-06-24 | — | — | WO | claimed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-20240077489-A1 | STYRYL PHENOLS, DERIVATIVES AND THEIR USE IN METHODS OF ANALYTE DETECTION | AAT BIOQUEST, INC. | 2024-03-07 | — | — | US | disclosed |
| US-5306438-A | Dielectric hydrophobic liquid carrier fluid with anionic dye particles; quick response | LORD CORPORATION (US) | 1994-04-26 | — | — | US | disclosed |
| US-5302639-A | Mixtures of nitrogen containing organic compound, anionic compound and a vinylpyrrolidone polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1994-04-12 | — | — | US | disclosed |
| WO-1993019143-A1 | COLORANT-CONTAINING ELECTRORHEOLOGICAL MATERIALS | LORD CORPORATION (US) | 1993-09-30 | — | — | WO | disclosed |
| WO-1993012192-A1 | IONIC DYE-BASED ELECTRORHEOLOGICAL MATERIALS | LORD CORPORATION (US) | 1993-06-24 | — | — | WO | disclosed |
| CN-1061977-A | The agent of polymkeric substance good antiscale property is used to prevent the aggregation container of polymer scale deposition, and uses this container to prepare the method for polymkeric substance | SHINETSU CHEMICAL CO (JP) | 1992-06-17 | — | — | CN | disclosed |
| US-5122432-A | Containing visible light absorber | THE MEAD CORPORATION (US) | 1992-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240077489-A1 | STYRYL PHENOLS, DERIVATIVES AND THEIR USE IN METHODS OF ANALYTE DETECTION | STUB1, SPR, HLCS | PTGS2 3828/4885PTGS1 3133/4885THRB 309/4885 |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | SLC5A2, SLC5A1, MAT1A | PTGS2 1265/4885PTGS1 1229/4885THRB 328/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | PTGS2 4216/4885PTGS1 4289/4885THRB 52/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | PTGS2 726/4885PTGS1 373/4885THRB 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.